Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. "Despite challenging market...
Endo International plc (NASDAQ: ENDP) today announced the upcoming launch of a new clinical study relevant to the use of Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate ...
Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar...
Endo International plc (NASDAQ: ENDP) today announced that the Tennessee Court of Appeals has reversed a trial court judge's order denying a motion for recusal by Endo's wholly-owned subsidiaries...
Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, ...
Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial. "We ...
Endo International plc (NASDAQ: ENDP) today honored select team members from across the world who exemplify Endo's Values as part of its inaugural Living Our Values Award program. "At Endo, we are...
Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance. "Endo's solid ...
Endo International plc (NASDAQ: ENDP) today announced that it expects a Tennessee state court to issue an order granting plaintiffs' request for a default judgment on liability against Endo's...
First and only manufacturer-prepared, FDA approved vasopressin in a premixed ready-to-use (RTU) format RTU format does not require diluting, or transferring, which may reduce waste and chance of...
Endo International plc (NASDAQ: ENDP) will announce its fourth–quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call...
Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. have entered into a statewide...
Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), announced today the launch of Xydalba® (dalbavancin for injection), a 30-minute intravenous (IV) therapy for acute bacterial...
Pharmacokinetic simulation modeling study predicted more frequent administration with shorter dosing intervals (8 weeks vs. 10 weeks) would reduce serum testosterone fluctuations and elevate...
Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022. He will join the...
The campaign features real Dupuytren's contracture (DC) patients and aims to address patient complacency, correct myths and misinformation and highlight the Tabletop Test Dupuytren's contracture is a ...
Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first generic version of Merz's CUVPOSA®...
Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. EST. A live webcast...
Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par...
Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals for the development, registration,...
Endo International plc (NASDAQ: ENDP) ("Endo") today announced that one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California...
Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval ...
Endo International plc (NASDAQ: ENDP) announced today that its Par Sterile Products business has begun shipping calcitonin salmon injection, USP, multi-dose vials (2 mL) following final approval from ...
Endo International plc (NASDAQ: ENDP) (Endo) today announced that its subsidiary, Par Sterile Products, LLC (Par Sterile), has entered into a cooperative agreement to expand its sterile fill-finish...
Endo International plc (NASDAQ: ENDP) today announced that its Par Sterile Products business will supply VASOSTRICT®, vasopressin injection, USP, vial presentations to healthcare providers through...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.